







Q

Home ▶ All Journals ▶ Medicine ▶ Leukemia & Lymphoma ▶ List of Issues ▶ Volume 49, Issue 11 ▶ Hydroxyurea, azacitidine and gemtuzumab

Leukemia & Lymphoma >

Volume 49, 2008 - <u>Issue 11</u>

599 51 6

Views CrossRef citations to date Altmetric

Original Articles: Clinical

Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial

Pages 2141-2147 | Received 16 Jun 2008, Accepted 27 Aug 2008, Published online: 01 Jul 2009



Full Article

Figures & data

References

66 Citations

Metrics

Reprints & Permissions

Read this article

Share

Abstract

Elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) have a poor prognosis due to low response rates (26–46%) to standard chemotherapy and high treatment-related mortality (11–31%). In this Phase II study, we used a combination of hydroxyurea (HU), azacitidine and low dose gemtuzumab ozogamicin (GO) to assess its efficacy and toxicity in this group of

patients. Twenty patients with non-M3 AML and MDS were treated with this regimen. The treatment was begun with HU 1500 mg orally twice daily to lower white blood cell count below 10,000/µL, followed by azacitidine 75 mg/m² subcutaneously for 7 days and GO 3 mg/m² on day 8. Patients who achieved complete remission (CR) received a consolidation course. The median age of patients was 76 years. Eleven patients (55%) were treated in the outpatient setting. Fourteen (70%) achieved a CR, three of which were incomplete (CRi). The median duration of remission was 8 months and median survival was 10 months. Performance status of 0–1 was associated with high complete response rate. Overall toxicity was acceptable with only one (5%) early death due to disease progression. The combination of HU, azacitdine and GO appears to be a safe and effective regimen in the treatment of AML and high risk MDS in the elderly. These results need to be confirmed in a larger cohort of patients.

Keywords:

Acute myeloid leukemia azacitidine gemtuzumab ozogamicin



People also read

Recommended articles

Cited by

Information for

Authors

R&D professionals

Editors

Librarians

Societies

Opportunities

Reprints and e-prints

Advertising solutions

Accelerated publication

Corporate access solutions

Open access

Overview

Open journals

Open Select

Dove Medical Press

F1000Research

Help and information

Help and contact

Newsroom

All journals

Books

Keep up to date

Register to receive personalised research and resources by email



Sign me up











Accessibility



Copyright © 2025 Informa UK Limited Privacy policy Cookies Terms & conditions



Registered in England & Wales No. 01072954 5 Howick Place | London | SW1P 1WG